Author review tools

Executive scientific summary

Records under Bridges HR correspond to a researcher publishing primarily on mitochondrial bioenergetics and respiratory complex I structure‑function and pharmacology. Her work combines high‑resolution structural biology (cryo‑EM), biochemistry and mechanistic pharmacology and has produced multiple widely cited papers that advanced molecular understanding of how biguanide drugs and other inhibitors interact with mammalian complex I Science complex I biguanide structural study Metformin and oxidative phosphorylation review.

Productivity and bibliometrics

• Works count reported ~53 and cumulative citations >2200 with an h index ~24 in OpenAlex records, indicating sustained influence in a focused field (mitochondrial complex I, biguanide pharmacology) rather than broad multidisciplinary output.
• Several first‑author and senior papers appear in high‑ranked journals (Biochemical Journal 2014, Nature Structural Molecular Biology 2018 contribution, Nature Communications, Science 2023) — these anchor her citation profile and indicate successful placement of mechanistic structural work in top venues Metformin and oxidative phosphorylation review CryoEM complex I structures 2018

Scientific strengths

1. Integration of structural biology and functional biochemistry: Bridges coauthored high‑resolution cryoEM structures of complex I and linked them to inhibition mechanisms, which is the gold standard for mechanistic claims in molecular bioenergetics CryoEM complex I structures 2018.
2. High‑impact placement and open data: Papers are published in high‑visibility journals with open access deposits for several works, increasing reproducibility and uptake Science complex I biguanide structural study.
3. Consistent thematic focus: A coherent research programme on complex I, its conformational states, ROS production and pharmacology — this focus increases cumulative expertise and allows progressive hypothesis testing across methods and models Complex I mutation ROS study 2021.

Limitations, blindspots and open questions

• Biological scope: The body of work is narrowly focused on mitochondrial complex I and pharmacological inhibitors; translational claims to whole‑organism drug effects require careful qualification because in vivo pharmacokinetics and tissue heterogeneity are not the same as in vitro biochemical states (authors generally note state and concentration dependence in papers) Metformin review caveats.
• Model diversity: Much structural work uses bovine or mouse heart mitochondria and purified complex I preparations; while biochemically precise, these models can omit cell type specific regulatory factors, post‑translational modifications, and accessory proteins that exist in disease states Ubiquinone binding cryoEM 2022.
• Potential citation concentration: Several high citation counts derive from a few anchor papers; while that is normal for focused mechanistic labs, it raises sensitivity of bibliometrics to landmark publications rather than broad community uptake.

Transparency and reproducibility

Multiple papers include open access PDFs or repository deposits, cryoEM maps and explicit methods; this level of data sharing supports reproducibility and independent reanalysis (e.g., Nature Communications and Science deposits) Inhibitor bound complex I 2020.

Conclusions and actionable takeaways

1. Scientific standing: Bridges HR (Hannah R Bridges) is a well‑established specialist in mitochondrial complex I structural biology and pharmacology whose work has produced multiple high‑quality, reproducible datasets that materially advanced mechanistic understanding of complex I inhibition Science complex I biguanide structural study.
2. Best next steps for readers: Read the 2014 Biochemical Journal synthesis together with the 2023 Science structural work to see how biochemical hypotheses matured into atomic mechanistic explanations; for translational claims, demand pharmacokinetic tissue exposure data and in vivo validations before extrapolating to clinical effects Metformin review and caveats.